<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Sunday Sept 24, 2017</th>
<th>Time/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate RTOG 0621</td>
<td>Experience-Based Quality Control in Radiation Therapy Treatment Planning of High Risk Post-prostatectomy Prostate Cancer with RapidPlan: NRG Oncology RTOG 0621</td>
<td>1:15 pm – 2:45 pm Poster Viewing Q&amp;A 1: GU, Biology QA 01 Location: Poster Hall Discussion: N/A CME: 0</td>
</tr>
<tr>
<td>Head &amp; Neck RTOG 0522</td>
<td>Knowledge Engineering–Based Quality Evaluation of NRG Oncology RTOG 0522 Treatment Plans</td>
<td>1:15 pm – 2:45 pm Physics ePoster Discussion 1 - Treatment Planning Location: Upper Level Rm 5B Discussion: 1:27 pm – 1:33 pm CME: 1.5</td>
</tr>
<tr>
<td>Head and Neck RTOG 0522</td>
<td>Head and Neck Squamous Cell Cancer Response Assessment Biomarkers: Unplanned Analysis of the NRG Oncology RTOG 0522 PET Substudy</td>
<td>1:15 pm – 2:45 pm Physics 1 – Imaging for Response Assessment Location: Upper Level Rm 31 A/B/C Discussion: 2:35 pm – 2:45 pm CME: 1.5</td>
</tr>
<tr>
<td>Prostate RTOG 0526</td>
<td>A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiation Therapy (NRG/RTOG0526): Initial Report of Late Toxicity Outcome</td>
<td>3:15 pm - 4:45 pm Clinical Trials Session Location: Ballroom 20 Discussion: 3:45 pm – 3:55 pm CME: 1.5</td>
</tr>
<tr>
<td>Lung RTOG 0915</td>
<td>Long-Term Follow-Up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients with Stage I Peripheral Non–small Cell Lung Cancer</td>
<td>4:45 pm – 6:15 pm Lung 1 – SBRT Location: Upper Level Rm 8 Discussion: 4:45 pm – 4:55 pm CME: 1.5</td>
</tr>
<tr>
<td>Lung RTOG 0617</td>
<td>Effect of PTV and Collimator Margins on Tumor Control for Patients with Stage III Non–small Cell Lung Cancer in NRG Oncology RTOG-0617.</td>
<td>4:45 pm - 6:15 pm Physics ePoster Discussion 2 - Outcome Analysis and Modeling Location: Upper Level Rm 5B Discussion: 4:45 pm - 4:55 pm CME: 1.5</td>
</tr>
<tr>
<td>Disease Site &amp; Study #</td>
<td>Monday Sept 25, 2017</td>
<td>Time/Location</td>
</tr>
<tr>
<td>Head and Neck RTOG 9003 RTOG 0129</td>
<td>Fractionation Schedule and Risk of Local-Regional Failure for Patients treated on NRG Oncology RTOG 9003 and 0129</td>
<td>10:45 am – 12:15 pm Chemoradiation for H&amp;N Cancer Location: Upper Level Rm 7 A/B Discussion: 11:45 am – 11:55 pm CME: 1.5</td>
</tr>
<tr>
<td>Head &amp; Neck RTOG 0129 &amp; RTOG 0522</td>
<td>Development of Laryngeal Cancer Nomograms From Pooled Data of Two Trials of Concurrent Chemoradiation: NRG Oncology RTOG 0129 and RTOG 0522.</td>
<td>10:45 am - 12:15 pm Chemoradiation for H&amp;N Cancer Location: Upper Level Rm 7 A/B Discussion: 11:55 am - 12:05 pm CME: 1.5</td>
</tr>
<tr>
<td>Pelvic GOG 0249</td>
<td>A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early stage endometrial cancer: A Gynecology Oncology Group Study</td>
<td>2:15 pm – 3:45 pm Plenary Session Location: Ballroom 20 Discussion: 2:35 pm – 2:45 pm CME: 1.5</td>
</tr>
<tr>
<td>Disease Site &amp; Study #</td>
<td>Tuesday Sept 26, 2017</td>
<td>Time/Location</td>
</tr>
<tr>
<td>------------------------</td>
<td>------------------------</td>
<td>---------------</td>
</tr>
</tbody>
</table>
| NSCLC RTOG 1308        | Knowledge Engineering–Based Quality Evaluation of RTOG 1308 Proton Treatment plans  
Presenter: Huaizhi Geng, PhD  
Abstract #: 3578 | 4:15 pm – 5:45 pm  
Poster Viewing Q&A 4: Physics QA 04  
Location: Poster Hall  
Discussion: N/A  
CME: 0 |
| NSCLC RTOG 1308        | Knowledge Engineering–Based Quality Evaluation of RTOG 1308 Photon Treatment Plans  
Presenter: Huaizhi Geng, PhD  
Abstract #: 3579 | 4:15 pm – 5:45 pm  
Poster Viewing Q&A 4: Physics QA 04  
Location: Poster Hall |
| Head & Neck HN001      | Establishing an Offline Evaluation Process for IMRT/VMAT Radiation Therapy Treatment Planning Quality Using Knowledge-Based Planning: A Study Based on Multi-institutional Head and Neck Clinical Trial  
Presenter: Tawfik Giaddui, PhD  
Abstract #: 3580 | 4:15 pm – 5:45 pm  
Poster Viewing Q&A 4: Physics QA 04  
Location: Poster Hall |
| Anal Canal RTOG 0529   | NRG Oncology/RTOG 0529: Long-Term Outcomes of Dose-Painted Intensity Modulated Radiation Therapy, 5-Fluorouracil, and Mitomycin-C in Anal Canal Cancer  
Presenter: Lisa Kachnic, MD, FASTRO  
Abstract #: 138 | 7:45 am – 9:00 am  
GI 1 – Anorectal Cancers  
Location: Upper Level Rm 1 A/B  
Discussion: 7:45 am – 7:55 am  
CME: 1.25 |
| Bladder, GU RTOG 0712  | Selective Bladder Preservation with Twice-Daily Radiation plus 5-Flourouracil/Cisplatin or Daily Radiation plus Gemcitabine for Patients with Muscle Invasive Bladder Cancer – Primary Results of NRG/RTOG 0712: A Randomized Phase 2 Multicenter Trial.  
Presenter: John Coen, MD  
Abstract #: LBA-12 (Oral SS22) | 7:45 am - 9:00 am  
Late-Breaking Abstracts Special Session  
Location: Upper Level Rm 5A  
Discussion: 8:21 am – 8:30 am  
CME: 1.25 |
| NSCLC RTOG 1106        | Evaluating the Feasibility of Applying Deformable Registration Into Adaptive Therapy for NRG Oncology RTOG 1106  
Presenter: Haoyu Zhong, MS  
Abstract #: 3208 | 1:00 pm – 2:30 pm  
Poster Viewing Q&A 5: Lung, Pediatrics, Education QA 05  
Location: Poster Hall |
| Head & Neck RTOG 0522   | A Feasibility Study on Incorporating Clinical Trial Quality Assurance Parameters into Outcome Prediction in Head and Neck Radiation Therapy Treatment  
Presenter: Jiazhou Wang, MS  
Abstract #: 2901 | 2:45 pm – 4:15 pm  
Poster Viewing Q&A 6: CNS, Head and Neck, Sarcoma QA06  
Location: Poster Hall |
| Head & Neck HN001      | Intersystem variability of Kilovoltage Conebeam Computed Tomography Imaging Guidance for Patients with Head and Neck Cancer: An NRG Oncology Multiple-institution study  
Presenter: Ping Xia, PhD  
Abstract #: 3339 | 4:45 pm – 6:15 pm  
Poster Viewing Q&A 7: GI, Hematologic QA 07  
Location: Poster Hall |
| Rectal RTOG 0830       | External Validation of the European Rectal Cancer Prognosis Model Using NRG Oncology RTOG 0830 Clinical Trial Data  
Presenter: Haoyu Zhong, MS  
Abstract #: 2494 | 4:45 pm – 6:15 pm  
Poster Viewing Q&A 7: GI, Hematologic QA 07  
Location: Poster Hall |
| Meningioma RTOG 0539   | High-Risk Meningioma: Initial Outcomes from NRG Oncology/ RTOG-0539  
Presenter: C. Leland Rogers, MD, FASTRO  
Abstract #: 214.5 | 4:45 pm – 6:15 pm  
CNS 1 - High Grade Gliomas, Neurotoxicity and Benign CNS Conditions  
Location: Upper Level Rm 31 A/B/C  
Discussion: 4:45 pm – 4:55 pm  
CME: 1.5 |
<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Wednesday Sept 27, 2017</th>
<th>Time/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bladder</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| RTOG 8802 | The Impact of MRE11 in Nuclear to Cytoplasmic Ratio on Outcomes in Muscle Invasive Bladder Cancer: an Analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233  
*Presenter:* Anthony Magliocco, MD  
*Abstract #:* 253 | 7:45 am – 9:00 am  
GU 2 - Emerging Data on Bladder Preservation  
*Location:* Upper Level Rm 30 D/E  
*Discussion:* 7:45 am – 7:55 am  
*CME:* 1.25 |
| RTOG 8903  
RTOG 9506  
RTOG 9706  
RTOG 9906  
RTOG 0233 | | |
| **Head & Neck** | | |
| RTOG 0522 | The Evidence Driven Dosimetric Constraints From Outcome Analysis of H&N Patients' Data from NRG Oncology RTOG 0522 Trial  
*Presenter:* Haoyu Zhong, MS  
*Abstract #:* 294 | 11:00 am – 12:30 pm  
Head and Neck 3 - Novel Approaches to the Treatment of Oropharynx Cancer  
*Location:* Upper Level Rm 11 A/B  
*Discussion:* 11:50 am – 12:00 pm  
*CME:* 1.5 |
| RTOG 9003  
RTOG 0129  
RTOG 0522 | Generalized Competing Event Regression to Stratify Head and Neck Cancer Patients: Secondary Analysis of NRG Oncology RTOG 9003, 0129, and 0522  
*Presenter:* Loren Mell, MD  
*Abstract #:* 1149 | 1:30 pm – 3:00 pm  
Head and Neck ePoster Discussion  
*Location:* Upper Level Rm 5A  
*Discussion:* 2:00 pm – 2:06 pm  
*CME:* 1.5 |
| **Lung** | | |
*Presenter:* Jian-Yue Jin, PhD  
*Abstract #:* 326  
(Oral SS43) | 1:30 pm - 3:00 pm  
Lung 4 - Toxicity  
*Location:* Upper Level Rm 30 D/E  
*Discussion:* 2:00 pm - 2:10 pm  
*CME:* 1.5 |
| **Rectal** | | |
| RTOG 0822  
RTOG 0247  
RTOG 0012 | Rectal Cancer Outcome Study Based on Multiple NRG Oncology Clinical Trials with Random Survival Forests  
*Presenter:* Mi Huang, PhD  
*Abstract #:* 361 | 3:15 pm - 4:45 pm  
Physics 9 – Outcome Analysis and Modeling 2  
*Location:* Upper Level Rm 4  
*Discussion:* 4:35 pm - 4:45 pm  
*CME:* 1.5 |